Thrombohemorrhagic Complications of COVID-19
Launched by VOLGOGRAD STATE MEDICAL UNIVERSITY · Jan 24, 2024
Trial Information
Current as of July 01, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to improve treatment for patients with COVID-19 who experience serious complications related to blood clots or bleeding. These complications, known as thrombohemorrhagic issues, can make the illness even more dangerous. The research will gather information from multiple hospitals across different cities that treated these patients during the pandemic. By analyzing this data, the goal is to create guidelines that help doctors better prevent and treat these complications in COVID-19 patients.
To be eligible for this study, patients need to have had thrombohemorrhagic complications while being treated in a COVID-19 hospital. However, patients with cancer, those who had similar blood issues before being admitted, pregnant women, and those who were already on blood-thinning medications before hospitalization will not be included. While the study is currently active, it is not recruiting new participants. Overall, the findings from this trial aim to improve outcomes for patients facing these serious complications related to COVID-19.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with thrombohemorrhagic complications who were treated in a covid hospital
- Exclusion Criteria:
- • Cancer patients
- • Patients who had thrombohemorrhagic disorders before admission to the hospital
- • Pregnant women
- • Patients receiving routine anticoagulant and antiplatelet therapy before admission to the hospital
About Volgograd State Medical University
Volgograd State Medical University is a prestigious educational and research institution dedicated to advancing medical science and healthcare. Located in Volgograd, Russia, the university is renowned for its commitment to clinical excellence, innovative research, and the training of skilled healthcare professionals. As a clinical trial sponsor, Volgograd State Medical University plays a pivotal role in conducting rigorous and ethical clinical research, contributing to the development of new therapies and improving patient outcomes. The university collaborates with various stakeholders in the medical field to ensure the highest standards of scientific integrity and patient safety in all its research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Volgograd, , Russian Federation
Patients applied
Trial Officials
Viktor Mikhin
Study Chair
Volgograd State Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported